Vera Therapeutics, Inc.

Vera Therapeutics, Inc. is a clinical stage biotechnology company focused on developing and commercializing treatments for patients with immunological diseases. Its lead product candidate is atacicept, a fully humanized TACI-Fc fusion protein that binds to B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL). Atacicept is being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and autoimmune kidney diseases, and is designed for self-administration at home as a subcutaneous injection. The company is also developing MAU868, a human monoclonal antibody for BK viremia infections that has completed a Phase 2 clinical trial, and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule targeting B cell mediated autoimmune diseases.

Vera Therapeutics, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol VERA. The company's shares are traded in US dollars (USD), reflecting its primary listing in the United States. As a Nasdaq-listed company, Vera Therapeutics is subject to the exchange's listing standards and reporting requirements, providing transparency for investors.

Vera Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on research and development of novel therapies for immunological diseases. The company's work involves advanced biologics such as fusion proteins and monoclonal antibodies, which are characteristic of the biotechnology field. This sector and industry classification highlights its role in developing innovative treatments that address unmet medical needs in areas like kidney disease and autoimmune disorders.

Vera Therapeutics is headquartered in Brisbane, California, United States. The company was incorporated in 2016 and was originally known as Trucode Gene Repair, Inc. before rebranding to Vera Therapeutics in April 2020. This rebranding marked a strategic shift in focus toward immunological diseases. The company serves the United States market primarily, as indicated by its US-based operations and Nasdaq listing. Its location in the San Francisco Bay Area places it within a major biotechnology hub, providing access to talent and research resources.

Vera Therapeutics' pipeline includes three key product candidates. The lead candidate is atacicept, a TACI-Fc fusion protein that inhibits BAFF and APRIL, currently being evaluated for immunoglobulin A nephropathy (IgAN) and autoimmune kidney diseases. It is designed for subcutaneous self-administration at home. Additionally, MAU868 is a human monoclonal antibody targeting BK viremia infections, which has completed a Phase 2 clinical trial. The company is also developing VT-109, a novel BAFF/APRIL dual-inhibitor BCMA molecule for B cell mediated autoimmune diseases. These candidates are all in clinical stages, reflecting the company's focus on immunological conditions.